R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 52.10
-0.65 (-1.23%)
At close: Sep 2, 2026
R&G PharmaStudies Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,064 | 5,666 | 4,756 | 6,190 | 4,940 | - | |
Market Cap Growth | 0.44% | 19.12% | -23.17% | 25.30% | - | - |
Enterprise Value | 3,442 | 3,960 | 3,124 | 4,564 | 3,498 | - |
Last Close Price | 52.75 | 59.37 | 49.67 | 63.69 | 50.68 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 42.25 | 41.39 | 33.92 | 38.09 | 43.55 | - |
Forward PE | 30.49 | 33.13 | 25.30 | 33.07 | - | - |
PS Ratio | 5.39 | 6.66 | 6.39 | 8.58 | 7.75 | - |
PB Ratio | 2.52 | 2.87 | 2.59 | 3.53 | 3.10 | - |
P/TBV Ratio | 2.67 | 3.04 | 2.75 | 3.58 | 3.14 | - |
P/FCF Ratio | 110.53 | 59.68 | 35.29 | 35.85 | 45.06 | - |
P/OCF Ratio | 79.62 | 49.61 | 30.73 | 32.15 | 37.87 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 3.66 | 4.65 | 4.20 | 6.33 | 5.49 | - |
EV/EBITDA Ratio | 23.88 | 30.62 | 21.64 | 29.69 | 31.68 | - |
EV/EBIT Ratio | 27.88 | 32.32 | 25.81 | 34.81 | 33.97 | - |
EV/FCF Ratio | 75.14 | 41.72 | 23.18 | 26.43 | 31.90 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.02 | 0.01 | 0.04 | 0.01 | 0.01 | 0.03 |
Debt / EBITDA Ratio | 0.29 | 0.13 | 0.46 | 0.05 | 0.13 | 0.08 |
Debt / FCF Ratio | 0.93 | 0.19 | 0.53 | 0.05 | 0.14 | 0.14 |
Net Debt / Equity Ratio | -0.81 | -0.88 | -0.93 | -0.97 | -0.94 | -0.80 |
Net Debt / EBITDA Ratio | -11.86 | -13.38 | -11.81 | -11.03 | -13.64 | -2.59 |
Net Debt / FCF Ratio | -35.57 | -18.22 | -12.65 | -9.82 | -13.74 | -4.60 |
Asset Turnover | 0.40 | 0.36 | 0.34 | 0.37 | 0.50 | 1.01 |
Inventory Turnover | 10.44 | 8.94 | 8.04 | 8.33 | 8.36 | 10.43 |
Quick Ratio | 5.64 | 5.44 | 4.73 | 6.20 | 6.25 | 2.35 |
Current Ratio | 5.81 | 5.60 | 4.88 | 6.38 | 6.45 | 2.58 |
Return on Equity (ROE) | 6.26% | 7.26% | 7.90% | 9.73% | 11.24% | 25.91% |
Return on Assets (ROA) | 3.27% | 3.23% | 3.43% | 4.14% | 5.03% | 11.35% |
Return on Invested Capital (ROIC) | 33.37% | 57.84% | 113.70% | 159.47% | 104.63% | 147.94% |
Return on Capital Employed (ROCE) | 6.10% | 6.10% | 6.40% | 7.50% | 6.40% | 24.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 2.37% | 2.42% | 2.95% | 2.63% | 2.30% | - |
FCF Yield | 0.90% | 1.68% | 2.83% | 2.79% | 2.22% | - |
Dividend Yield | 0.25% | 0.27% | 0.32% | 0.31% | 0.31% | - |
Payout Ratio | 12.84% | 8.61% | 20.24% | 3.58% | - | - |
Buyback Yield / Dilution | -1.20% | -0.36% | 0.64% | -16.78% | -14.43% | 0.38% |
Total Shareholder Return | -0.95% | -0.09% | 0.96% | -16.46% | -14.12% | 0.38% |